Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (22)

In this article, we will discuss Ramucirumab (22). So, let’s get started.

Clinical Trials Experience (3)

Clinically relevant adverse reactions reported in ≥1% and <5% of Ramucirumab-treated patients in Study 1 were: neutropenia (4.7% Ramucirumab versus 0.9% placebo), epistaxis (4.7% Ramucirumab versus 0.9% placebo), rash (4.2% Ramucirumab versus 1.7% placebo), intestinal obstruction (2.1% Ramucirumab versus 0% placebo), and arterial thromboembolic events (1.7% Ramucirumab versus 0% placebo).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.